These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

639 related items for PubMed ID: 23562009

  • 1. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
    Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G, SELECT study investigators.
    Lancet; 2013 Jun 22; 381(9884):2167-75. PubMed ID: 23562009
    [Abstract] [Full Text] [Related]

  • 2. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
    Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G, SELECTION Study Investigators.
    Lancet Neurol; 2014 May 22; 13(5):472-81. PubMed ID: 24656609
    [Abstract] [Full Text] [Related]

  • 3. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr 22; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 4. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J.
    N Engl J Med; 2015 Oct 08; 373(15):1418-28. PubMed ID: 26444729
    [Abstract] [Full Text] [Related]

  • 5. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
    Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL.
    Lancet; 2011 Nov 19; 378(9805):1779-87. PubMed ID: 22047971
    [Abstract] [Full Text] [Related]

  • 6. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L, TOWER Trial Group.
    Lancet Neurol; 2014 Mar 19; 13(3):247-56. PubMed ID: 24461574
    [Abstract] [Full Text] [Related]

  • 7. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.
    Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, Greenberg SJ, Sweetser M, Castro-Borrero W, McCroskery P, Elkins J.
    Adv Ther; 2016 Jul 19; 33(7):1231-45. PubMed ID: 27251051
    [Abstract] [Full Text] [Related]

  • 8. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
    Havrdova E, Giovannoni G, Stefoski D, Forster S, Umans K, Mehta L, Greenberg S, Elkins J.
    Mult Scler; 2014 Apr 19; 20(4):464-70. PubMed ID: 24022270
    [Abstract] [Full Text] [Related]

  • 9. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, ADVANCE Study Investigators.
    Lancet Neurol; 2014 Jul 19; 13(7):657-65. PubMed ID: 24794721
    [Abstract] [Full Text] [Related]

  • 10. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study.
    Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH, Ustekinumab MS Investigators.
    Lancet Neurol; 2008 Sep 19; 7(9):796-804. PubMed ID: 18703004
    [Abstract] [Full Text] [Related]

  • 11. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun 19; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
    Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J.
    BMC Neurol; 2016 Jul 26; 16():117. PubMed ID: 27461166
    [Abstract] [Full Text] [Related]

  • 13. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M, Sørensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, Bartholomé E, Constantinescu CS, Beer K, Garde E, Sperling B.
    Lancet Neurol; 2010 Jul 26; 9(7):672-80. PubMed ID: 20542736
    [Abstract] [Full Text] [Related]

  • 14. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
    Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.
    Lancet Neurol; 2014 Jun 24; 13(6):545-56. PubMed ID: 24685276
    [Abstract] [Full Text] [Related]

  • 16. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L, Hartung HP, Freedman MS, Boyko A, Radü EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J, ATAMS Study Group.
    Lancet Neurol; 2014 Apr 24; 13(4):353-63. PubMed ID: 24613349
    [Abstract] [Full Text] [Related]

  • 17. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, CARE-MS II investigators.
    Lancet; 2012 Nov 24; 380(9856):1829-39. PubMed ID: 23122650
    [Abstract] [Full Text] [Related]

  • 18. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
    Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB, SIMCOMBIN study investigators.
    Lancet Neurol; 2011 Aug 24; 10(8):691-701. PubMed ID: 21742556
    [Abstract] [Full Text] [Related]

  • 19. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
    Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ.
    Clin Pharmacokinet; 2016 Aug 24; 55(8):943-55. PubMed ID: 26873229
    [Abstract] [Full Text] [Related]

  • 20. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr KM, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M, PreCISe study group.
    Lancet; 2009 Oct 31; 374(9700):1503-11. PubMed ID: 19815268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.